Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer
Immuneering presented new data at the 2026 AACR Conference on Pancreatic Cancer supporting atebimetinib + mGnP's dual mechanism of tumor volume reduction and body mass preservation in first-line pancreatic cancer. In exploratory post-hoc analyses from the Phase 2a study, stable or increased weight was roughly twice as common among treated patients (n=23) versus a published benchmark, and weight-stable patients had significantly longer overall survival (HR=3.13; p=0.049).
Key figures
- Drug Name
- atebimetinib
- Phase Of Trial
- Phase 2a (supportive); Phase 3 MAPKeeper 301 ongoing
- Os patients
- 55
- Weight analysis n
- 23
- Weight trajectory hr
- 3.13
- Faact acs improvement pct
- 66%
- Weight trajectory p value
- 0.049
- Median overall survival months
- 17.3
- Pct stable or increased weight
- 84%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.